Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy with CDDP.

A Restaino1, V Traina, G Putignano

  • 1I Gynaecological Institute, University of Bari, Italy.

European Journal of Gynaecological Oncology
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Can the endometrioma be an obstacle to complete oocyte retrieval in IVF cycles? A retrospective study.

European review for medical and pharmacological sciences·2026
Same author

Progesterone peak influences embryonic developmental morphokinetics on trigger day? A retrospective study.

Journal of ovarian research·2024
Same author

Can the endometrioma be an obstacle to complete oocyte retrieval in IVF cycles? A retrospective study.

European review for medical and pharmacological sciences·2024
Same author

Obesity does not increase the risk of side effects and complications of egg retrieval: delaying oocyte retrieval in obese patients is not a good strategy.

European review for medical and pharmacological sciences·2023
Same author

Evaluation of the ideal vaginal Progesterone effectiveness doses for luteal support in embryo thawing cycles after endometrial preparation without using the GnRh analogue.

European review for medical and pharmacological sciences·2023
Same author

Effects of a combination of resveratrol and alpha-lipoic acid on body weight and adipose composition in women with PCOS: a preliminary pilot study.

European review for medical and pharmacological sciences·2022
Same journal

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study.

European journal of gynaecological oncology·2023
Same journal

Sclerosing stromal tumor of the ovary in a perimenopausal woman: a case report.

European journal of gynaecological oncology·2018
Same journal

Chemotherapy-induced differentiation to cure botryoid rhabdomyosarcoma: a case report and review of the literature.

European journal of gynaecological oncology·2018
Same journal

Mixed endometrial stromal and smooth muscle tumor of the uterus in a postmenopausal woman: morphologic and immunohistochemical features.

European journal of gynaecological oncology·2018
Same journal

Retroperitoneal primitive neuroectodermal tumor (PNET): case report and review of literature.

European journal of gynaecological oncology·2018
Same journal

Advanced stage yolk sac ovarian tumour: clinical approach with cytoreductive surgery upfront.

European journal of gynaecological oncology·2018
See all related articles

This study on ovarian carcinoma patients found that monitoring kidney function (nephrologic monitoring) enables safer and more effective cisplatin chemotherapy. This approach improves the cost-benefit ratio of treatment.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Ovarian carcinoma treatment often involves chemotherapy, with cisplatin (CDDP) being a common agent.
  • Chemotherapy can lead to kidney toxicity (tubulo-toxicity), necessitating careful monitoring.
  • Evaluating enzymuria is a reliable method for detecting both acute and chronic kidney damage.

Purpose of the Study:

  • To assess the efficacy and safety of different chemotherapy administration routes (parenteral and intraperitoneal) in ovarian carcinoma patients.
  • To investigate the role of nephrologic monitoring in managing cisplatin-induced tubulo-toxicity.
  • To determine the cost-benefit relationship of cisplatin chemotherapy with adequate renal function assessment.

Main Methods:

  • Retrospective analysis of 30 ovarian carcinoma patients treated with chemotherapy.

Related Experiment Videos

  • 27 patients received parenteral chemotherapy (mono- or poly-chemotherapy with CDDP and alkylating agents).
  • 3 patients received low-dose intraperitoneal cisplatin. Enzymuria was measured pre- and post-therapy in 27 cases.

    • Main Results:

    • Chemotherapy regimens included cisplatin (CDDP) monotherapy and poly-chemotherapy (CDDP + alkylating agents).
    • Enzymuria evaluation served as a key indicator for assessing kidney tubule damage.
    • Nephrologic monitoring was found to facilitate more precise cisplatin usage.

    Conclusions:

    • Careful nephrologic monitoring is crucial for optimizing cisplatin chemotherapy in ovarian cancer.
    • This monitoring enhances treatment accuracy and improves the overall cost-benefit ratio.
    • Enzymuria is a valuable biomarker for detecting and managing cisplatin-related kidney toxicity.